RxDoctor Payments Data

Anantha Brahmamdam, MD

Internal Medicine · Cincinnati, OHNPI 1497702039

Payments from drug & device makers

$1,109in general payments, 2019–2025

Across 29 payments — averaging $38.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$616
  • AstraZeneca$148
  • Madrigal Pharmaceuticals$122
  • Lilly USA, LLC$66
  • Astellas Pharma US Inc$57
  • Ironwood Pharmaceuticals, Inc$37
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$1,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,109 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$48,937
Medicare patients
150
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$50,841
EliquisApixaban23$32,142
MounjaroTirzepatide25$31,167
XareltoRivaroxaban15$20,523
SymbicortBudesonide/Formoterol Fumarate27$9,259
Breo ElliptaFluticasone/Vilanterol13$4,428
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,792
Atorvastatin Calcium315$2,305
Lubiprostone15$2,107
Rosuvastatin Calcium187$2,097
Albuterol Sulfate HfaAlbuterol Sulfate94$1,909
Potassium Chloride73$1,715
Levothyroxine Sodium177$1,248
Gabapentin95$1,232
Amlodipine Besylate246$1,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$50,84151 claims
Lilly USA, LLCMounjaro$66$31,16725 claims
AstraZenecaSymbicort$148$9,25927 claims
AbbVieSynthroid$616$67624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →